---
title: "Highest 1-Year OS Rate! iza-bren Combined with Sintilimab Achieves 8.2 Months mPFS and 85.7% 1-Year OS Rate in First-Line Extensive-Stage Small Cell Lung Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280549940.md"
description: "At the European Lung Cancer Congress held in Copenhagen, Denmark, from March 25 to 28, 2026, the clinical research results of Biokin Pharmaceutical's iza-bren (EGFR×HER3 bispecific ADC) combined with sintilimab were selected for oral presentation, showing that this treatment regimen achieved an mPFS of 8.2 months and a 1-year OS rate of 85.7% in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)"
datetime: "2026-03-26T01:41:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280549940.md)
  - [en](https://longbridge.com/en/news/280549940.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280549940.md)
generator: "portal-rs"
---

# Highest 1-Year OS Rate! iza-bren Combined with Sintilimab Achieves 8.2 Months mPFS and 85.7% 1-Year OS Rate in First-Line Extensive-Stage Small Cell Lung Cancer

From March 25 to 28, 2026, at the European Lung Cancer Congress (2026 ELCC) held in Copenhagen, Denmark, the clinical research results of Biokin Pharmaceutical's independently developed iza-bren (EGFR×HER3 bispecific ADC) combined with sintilimab for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) were successfully selected for oral presentation at the congress.

### Related Stocks

- [688506.CN](https://longbridge.com/en/quote/688506.CN.md)

## Related News & Research

- [Stock futures poised to trade ahead of Fed rate decision](https://longbridge.com/en/news/298837616.md)
- [Bond rout could blow a huge hole in the UK's finances and risk a repeat of 1976, warns Hamish McRae](https://longbridge.com/en/news/298824619.md)
- [MORE ECB MINUTES: GOVERNING COUNCIL REITERATES THAT IT IS NOT PRE-COMMITTING TO A PARTICULAR RATE PATH](https://longbridge.com/en/news/298593899.md)
- [Does the Fed really control the market?](https://longbridge.com/en/news/298776881.md)
- [Calgro M3 director associate buys shares worth R 6.34 million](https://longbridge.com/en/news/298742037.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**